文献速递肝肾功能剂量调整

雷莫芦单抗在癌症患者中的群体药代动力学荟萃分析

Population pharmacokinetic meta-analysis of ramucirumab in cancer patients.
PubMed 文献 · Br J Clin Pharmacol · 2017-09-27

该分析纳入11项临床试验中1639例多种癌症患者的6427份血清浓度数据,采用群体药代动力学方法建立二室模型,典型68 kg患者的清除率、分布容积和半衰期分别为0.0148 l h⁻¹、5.30 l和13.4天,体重与药物处置存在适度关系,支持按体重归一化给药,轻中度肾功能损害或轻度肝功能损害无需调整剂量。

要点

  • 雷莫芦单抗药代动力学符合二室模型,典型68 kg患者半衰期13.4天。
  • 体重影响清除率和中央室容积,支持按体重归一化给药方案。
  • 轻中度肾功能损害或轻度肝功能损害患者无需调整剂量。

核心结论

  • 最终模型充分描述了雷莫芦单抗在多种癌症适应症患者中的浓度-时间曲线。
  • 模型证实按体重归一化的给药方案适用于雷莫芦单抗治疗。
  • 轻中度肾功能损害或轻度肝功能损害患者无需调整剂量。

研究设计与样本

  • 分析纳入11项1b期、2期和3期临床试验中1639例多种癌症患者的6427份血清浓度数据。
  • 雷莫芦单抗以8 mg kg⁻¹每2周或10 mg kg⁻¹每3周经1小时静脉输注给药。
  • 开发系列药效统计学模型描述浓度数据,并用最佳模型评估患者因素对药代动力学的影响。

主要发现

  • 雷莫芦单抗药代动力学由二室模型良好表征。
  • 典型68 kg患者的清除率、分布容积和半衰期均值分别为0.0148 l h⁻¹、5.30 l和13.4天。
  • 体重与雷莫芦单抗处置存在适度关系,清除率和中央室容积随体重增加。
  • 在该患者群体中未发现其他患者特征影响雷莫芦单抗处置。

关键数值与推荐

  • 典型68 kg患者清除率0.0148 l h⁻¹、分布容积5.30 l、半衰期13.4天。
  • 给药方案为8 mg kg⁻¹每2周或10 mg kg⁻¹每3周静脉输注。
  • 轻中度肾功能损害或轻度肝功能损害无需剂量调整。

临床怎么用

  • 临床可按体重归一化方案(8 mg kg⁻¹每2周或10 mg kg⁻¹每3周)给予雷莫芦单抗。
  • 轻中度肾功能损害或轻度肝功能损害患者使用雷莫芦单抗时无需调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Ramucirumab is a human IgG1 monoclonal antibody that specifically binds vascular endothelial growth factor receptor-2 (VEGFR-2) and blocks binding of VEGF-A, VEGF-C and VEGF-D. The objective of the analysis was to characterize the clinical pharmacology profile of ramucirumab using a population pharmacokinetic approach. METHODS: A total of 1639 patients with 6427 serum concentrations from 11 Phase 1b, 2 and 3 clinical trials in patients with various cancer indications were included in the analysis. Ramucirumab was administered as an intravenous infusion over 1 h at 8 mg kg-1 every 2 weeks or 10 mg kg-1 every 3 weeks. A series of pharmacostatistical models were developed to describe the concentration data. The best model was used to evaluate patient factors for their effect on ramucirumab pharmacokinetics. RESULTS: The pharmacokinetics of ramucirumab were well characterized by a two-compartment model. Mean population estimates of clearance, volume of distribution and half-life for a typical 68-kg patient were 0.0148 l h-1 , 5.30 l and 13.4 days, respectively. A modest relationship was observed between body weight and ramucirumab disposition; clearance and central compartment volume increased with body weight. No other patient characteristics were shown to influence the disposition of ramucirumab in this patient population. CONCLUSIONS: The final model adequately described the concentration-time profile of ramucirumab in patients with a range of cancer indications. The model confirmed that a weight-normalized dosing regimen is appropriate for ramucirumab therapy. Dose adjustment was not required for patients with mild to moderate renal impairment or mild hepatic impairment.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. O'Brien L, Westwood P, Gao L, et al. Population pharmacokinetic meta-analysis of ramucirumab in cancer patients. Br J Clin Pharmacol. 2017. PMID: 28833321. doi:10.1111/bcp.13403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。